The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A new approach to delay the development of resistance to docetaxel in the treatment of castration-refractory prostate cancer.
S. Filleur
No relevant relationships to disclose
S. R. Sennoune
No relevant relationships to disclose
J. C. Lees
No relevant relationships to disclose
J. Hirsch
No relevant relationships to disclose
L. Bermudez
No relevant relationships to disclose
R. Martinez-Zaguilan
No relevant relationships to disclose
T. Nelius
No relevant relationships to disclose